Last Updated: June 2023
Table 1. Estimated risk of HIV transmission by exposure Table 2. Recommendations for PEP Table 3. Characteristics of dolutegravir vs raltegravir when used as the third agent for PEP Table 4. Laboratory assessment of people who are prescribed PEP Table 5. PEP in the context of PrEP Figure 1. Recommended regimens for PEP Appendix A, …
Refer to the table below for relevant support on PEP prescribing in your jurisdiction.
Patient information about PEP is available from the Get PEP website. Local AIDS councils and health departments can also provide further information. Link to AIDS councils are available via Health Equity Matters (HEM, formerly AFAO). A brief one-page patient summary of PEP is contained here in multiple languages.
Estimated HIV acquisition risk if source is viraemic, by population group IAI: insertive anal intercourse IVI: insertive vaginal intercourse RAI: receptive anal intercourse RVI: receptive vaginal intercourse IAI: insertive anal intercourse IVI: insertive vaginal intercourse RAI: receptive anal intercourse RVI: receptive vaginal intercourse IAI: insertive anal intercourse IVI: insertive vaginal intercourse RAI: receptive anal intercourse …
Appendix A: Estimated HIV acquisition risk if source is viraemic, by population group Read More »
Evidence for three-drug versus two-drug PEP regimens PEP regimens may consist of two or three antiretroviral drugs. There is no direct nor compelling indirect evidence to support the greater efficacy of three- over two-drug regimens; rather, it has been extrapolated from evidence that a higher number of drugs or combination of drug classes have historically …
Appendix B: Evidence for three-drug versus two-drug PEP regimens Read More »
Cost of PEP regimens a costs correct as at 22 September 2022 b cost unchanged irrespective of dosage or whether taken daily or twice daily
A multidisciplinary Expert Reference Group (see Acknowledgements) was convened by the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) in March 2022. The updated guideline is based on a comprehensive literature review conducted by a trained librarian from an Expert Reference Group member’s Institution (Walter McGrath Library, St Vincent’s Hospital, Sydney). The …
Palich R, Martin-Blondel G, Cuzin L, et al. Experiences of HIV postexposure prophylaxis (PEP) among highly exposed men who have sex with men (MSM). Sex Transm Infect 2017;93:493-8. Gianacas C, Down I, Ellard J, et al. Experiences of HIV: The Seroconversion Study Final Report 2007–2015. Monograph, The Kirby Institute, UNSW Australia; 2015. …
Disclosure of gender identity and history is not necessary for the provision of PEP and should always be optional. This is particularly important for patients with transgender experience, non-binary, or fluid gender identities. Evidence for HIV prevalence and risk among trans and gender-diverse people in Australia is poor due to limitations with data collection and …
These guidelines are pending endorsement by the Blood Borne Viruses and Sexually Transmitted Infections Standing Committee (BBVSS).
Funded By: The Australian Government Department of Health
Disclaimer: Whilst the Australian Department of Health provides financial assistance to ASHM Health, the material contained in this resource produced by us should not be taken to represent the views of the Australian Department of Health.
The content of this resource is the sole responsibility of ASHM Health.
We acknowledge that ASHM Health offices are located on the land of the Gadigal peoples of the Eora Nation (Sydney Office) and the Turrbal and Jagera/Yuggera peoples (Brisbane Office) who are the Traditional Owners of the lands where both offices are situated. We pay our respects to Elders past and present.
ABN 48 264 545 457 | CFN 17788
Copyright © 2023 ASHM Health